{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:39:24Z","timestamp":1789173564046,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"High-level public health technical talents of the Beijing Municipal Health Commission","award":["XUEKEGUGAN-010-018"],"award-info":[{"award-number":["XUEKEGUGAN-010-018"]}]},{"DOI":"10.13039\/501100010909","name":"Young Scientists Fund","doi-asserted-by":"publisher","award":["82103902"],"award-info":[{"award-number":["82103902"]}],"id":[{"id":"10.13039\/501100010909","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s12072-022-10415-7","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T13:05:20Z","timestamp":1670245520000},"page":"52-62","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"17","author":[{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2586-1443","authenticated-orcid":false,"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"10415_CR1","doi-asserted-by":"crossref","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211\u20131259.","DOI":"10.1016\/S0140-6736(17)32154-2"},{"issue":"6","key":"10415_CR2","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"Polaris Observatory Collaborators","year":"2018","unstructured":"Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10003","key":"10415_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546\u20131555","journal-title":"Lancet"},{"issue":"5","key":"10415_CR4","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3201\/eid2305.161477","volume":"23","author":"F Cui","year":"2017","unstructured":"Cui F, Shen L, Li L, et al. Prevention of Chronic Hepatitis B after 3 Decades of Escalating Vaccination Policy. China Emerg Infect Dis. 2017;23(5):765\u2013772","journal-title":"China Emerg Infect Dis"},{"issue":"4","key":"10415_CR5","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.jhep.2013.05.016","volume":"59","author":"EM Sokal","year":"2013","unstructured":"Sokal EM, Paganelli M, Wirth S, et al. Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology Hepatology and Nutrition. J Hepatol. 2013;59(4):814\u2013829","journal-title":"J Hepatol"},{"issue":"1","key":"10415_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12876-017-0657-y","volume":"17","author":"Y Xu","year":"2017","unstructured":"Xu Y, Wang X, Liu Z, et al. Addition of nucleoside analogues to peg-IFN\u03b1-2a enhances virological response in chronic hepatitis B patients without early response to peg-IFN\u03b1-2a: a randomized controlled trial. BMC Gastroenterol. 2017;17(1):102","journal-title":"BMC Gastroenterol"},{"issue":"13","key":"10415_CR7","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/hepr.13227","volume":"48","author":"H Tajiri","year":"2018","unstructured":"Tajiri H, Takano T, Tanaka Y, Murakami J, Brooks S. Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infection. Hepatol Res. 2018;48(13):1172\u20131177","journal-title":"Hepatol Res"},{"issue":"6","key":"10415_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.jhep.2018.01.037","volume":"68","author":"S Zhu","year":"2018","unstructured":"Zhu S, Zhang H, Dong Y, et al. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol. 2018;68(6):1123\u20131128","journal-title":"J Hepatol"},{"key":"10415_CR9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928","journal-title":"BMJ"},{"issue":"9","key":"10415_CR10","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u2013605","journal-title":"Eur J Epidemiol"},{"issue":"7382","key":"10415_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","volume":"326","author":"DG Altman","year":"2003","unstructured":"Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219","journal-title":"BMJ"},{"issue":"03","key":"10415_CR12","first-page":"214","volume":"27","author":"J Pan","year":"2020","unstructured":"Pan J, Zhang M, Yao TT, et al. Efficiency and influencing factors of interferon therapy for 1\u20136 years old children with chronic hepatitis B. Int J Virol. 2020;27(03):214\u2013218 (In Chinese)","journal-title":"Int J Virol"},{"issue":"6","key":"10415_CR13","doi-asserted-by":"publisher","first-page":"846","DOI":"10.24953\/turkjped.2019.06.004","volume":"61","author":"\u0130Y Bajin","year":"2019","unstructured":"Bajin \u0130Y, Demir H, Salt\u0131k-Temizel \u0130N, \u00d6zen H, Y\u00fcce A. Long term follow-up of children with chronic hepatitis B: a single center experience. Turk J Pediatr. 2019;61(6):846\u2013851","journal-title":"Turk J Pediatr"},{"issue":"4","key":"10415_CR14","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12664-018-0878-1","volume":"37","author":"BB Lal","year":"2018","unstructured":"Lal BB, Sood V, Khanna R, Rawat D, Verma S, Alam S. Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B-First study in children. Indian J Gastroenterol. 2018;37(4):326\u2013334","journal-title":"Indian J Gastroenterol"},{"key":"10415_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5152\/etd.2013.01","volume":"35","author":"M Canpolat","year":"2013","unstructured":"Canpolat M, Arslan D, Soyuer I. Long term follow-up, treatment and prognosis of chronic hepatitis B patients in childhood. Erciyes Tip Dergisi. 2013;35:1 (6-12)","journal-title":"Erciyes Tip Dergisi."},{"issue":"11","key":"10415_CR16","first-page":"139","volume":"3","author":"JL Teng","year":"2009","unstructured":"Teng JL. Effect of lamivudine for children with chronic hepatitis B. Chin J Mod Drug Appl. 2009;3(11):139 (In Chinese)","journal-title":"Chin J Mod Drug Appl."},{"issue":"4","key":"10415_CR17","first-page":"102","volume":"28","author":"ZR Huang","year":"2008","unstructured":"Huang ZR. Effect of lamivudine combined with interferon \u03b1 for children with chronic hepatitis B. Clin Med. 2008;28(4):102\u2013103 (In Chinese)","journal-title":"Clin Med"},{"issue":"14","key":"10415_CR18","first-page":"11","volume":"46","author":"SJ He","year":"2008","unstructured":"He SJ, Chen J. Effect of Interferon \u03b1-2b combined with lamivudine in positive HBeAg chronic hepatitis B children. China Modern Doctor. 2008;46(14):11-12,15 (In Chinese)","journal-title":"China Modern Doctor"},{"issue":"1","key":"10415_CR19","first-page":"62","volume":"21","author":"XH Zhong","year":"2007","unstructured":"Zhong XH, Deng X, Chen XC, Zhou BP. Comparison of different combination therapies for children with HBeAg positive chronic hepatitis B. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007;21(1):62\u201363 (In Chinese)","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"issue":"5","key":"10415_CR20","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/MPG.0b013e31815604fb","volume":"45","author":"Z Kuloglu","year":"2007","unstructured":"Kuloglu Z, Krsa\u00e7loglu CT, Kansu A, Erden E, Girgin N. Liver histology of children with chronic hepatitis treated with interferon-alpha alone or in combination with lamivudine. J Pediatr Gastroenterol Nutr. 2007;45(5):564\u2013568","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10415_CR21","first-page":"136","volume":"25","author":"S Sokucu","year":"2006","unstructured":"Sokucu S, Gok\u00e7e S, Suoglu OD, Emiroglu H, Cevikbas U. Comparison of interferon monotherapy with interferon-lamivudine combination treatment in children with chronic hepatitis B. Indian J Gastroenterol. 2006;25(3):136\u2013139","journal-title":"Indian J Gastroenterol"},{"issue":"5","key":"10415_CR22","first-page":"19","volume":"6","author":"XH Zhong","year":"2004","unstructured":"Zhong XH. Efficacy of interferon \u03b1-2b and lamivudine therapy for chronic hepatitis B in children. Modern Med J China. 2004;6(5):19\u201320 (In Chinese)","journal-title":"Modern Med J China"},{"issue":"2","key":"10415_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1440-1746.2004.03209.x","volume":"19","author":"B Dikici","year":"2004","unstructured":"Dikici B, Ozgenc F, Kalayci AG, et al. Current therapeutic approaches in childhood chronic hepatitis B infection: a multicenter study. J Gastroenterol Hepatol. 2004;19(2):127\u2013133","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"10415_CR24","first-page":"316","volume":"45","author":"T Do\u01e7anci","year":"2003","unstructured":"Do\u01e7anci T. \u03b1Interferon and Lamivudine Treatment in Children with Chronic Hepatitis B. Gulhane Med J. 2003;45(4):316\u2013320","journal-title":"Gulhane Med J"},{"issue":"4","key":"10415_CR25","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1046\/j.1442-200X.2002.01589.x","volume":"44","author":"MA Selimoglu","year":"2002","unstructured":"Selimoglu MA, Aydogdu S, Unal F, Zeytinoglu A, Y\u00fcce G, Yagci RV. Alpha interferon and lamivudine combination therapy for chronic hepatitis B in children. Pediatr Int. 2002;44(4):404\u2013408","journal-title":"Pediatr Int"},{"issue":"5","key":"10415_CR26","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1046\/j.1442-200X.2002.01607.x","volume":"44","author":"B Dikici","year":"2002","unstructured":"Dikici B, Bosnak M, Bosnak V, et al. Comparison of treatments of chronic hepatitis B in children with lamivudine and alpha-interferon combination and alpha-interferon alone. Pediatr Int. 2002;44(5):517\u2013521","journal-title":"Pediatr Int"},{"issue":"1","key":"10415_CR27","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/S0168-8278(01)80649-8","volume":"34","author":"SH Engler","year":"2001","unstructured":"Engler SH, Stremmel W, Kalinowski BI. Interferon alpha2A induction therapy in combination with ribavirin and amantadine in naive patients with chronic HCV infection (abstract). J Hepatol. 2001;34(1):177","journal-title":"J Hepatol"},{"issue":"3","key":"10415_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/j.gastro.2018.10.027","volume":"156","author":"YH Yeo","year":"2019","unstructured":"Yeo YH, Ho HJ, Yang HI, et al. Factors associated with rates of HBsAg seroclearance in adults with chronic HBV infection: a systematic review and meta-analysis. Gastroenterology. 2019;156(3):635-646.e9","journal-title":"Gastroenterology"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-022-10415-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-022-10415-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T17:46:39Z","timestamp":1675359999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-022-10415-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10415"],"URL":"https:\/\/doi.org\/10.1007\/s12072-022-10415-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"25 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Min Li, Qinghong Li, Jianhui Qu, Huiyin Yang, Tingting Lv, Yuanyuan Kong, Hongfei Zhang have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}